In a similar model of prolonged ethanol administration to mice, Iracheta-Vellve et al.23 explored the role of a TGR5 agonist and a combined TGR5 and FXR agonist and showed that TGR5 activation decreased hepatic steatosis, protected the mice from liver injury by modulating lipogenic gene expression, and decreased liver IL-1β levels. The gene discussed is IL1B; the disease is Hepatic steatosis.